OTCQB:FUNI
Hypha Labs (OTCQB:FUNI) believes it is at the juncture of two rivers, one regulatory and one scientific, converging to create an unparalleled opportunity for a first mover to deliver to an awaiting public the first home unit designed to create perfect mushroom compounds.
01
02
We carefully crafted the Hypha Home Bioreactor, a compact device designed to simplify the production of enriched mycelium of functional mushrooms. This groundbreaking innovation allows individuals to cultivate therapeutic mushrooms as quickly as brewing coffee at home.
Functional Mushrooms have shown significant promise in clinical studies for treating mental health conditions such.
Traditional mushroom cultivation requires extensive infrastructure and costly lab equipment, posing significant barriers to small-scale producers. Hypha Labs addresses this issue with our innovative bioreactor technology, which reduces costs, simplifies the process, and ensures safe, high-quality functional mushroom production, making it accessible to a broader audience.
At Hypha Labs, we are committed to advancing biotechnology and health solutions. Our latest achievement is the filing of a new patent, which highlights our dedication to pioneering new technologies in the industry.
On May 23, 2024, we proudly announced this significant milestone. This new patent represents a crucial step forward in our research and development efforts, emphasizing our mission to bring groundbreaking technologies to market. Our work in this area is not only innovative but also transformative, aiming to enhance health and well-being.
01
02
Our continuous efforts in research and development reflect our commitment to pushing the boundaries of science and technology.
By exploring the therapeutic potentials of functional mushrooms, we are at the forefront of a revolutionary industry.
01
03
Envisioning a future where the scientifically validated nutritional and medicinal properties of mushrooms become a cornerstone of daily health regimes worldwide, facilitated by our cutting-edge biotechnology.
02 Functional mushrooms offer a wealth of scientifically-proven health benefits, from boosting immunity to reducing inflammation.
Our innovative solutions make it easy for anyone to grow and consume these incredible superfoods at home.
04
Precise control over environmental conditions in the bioreactor ensures consistent potency and quality of the final product.
01
02
To revolutionize global health and wellness by harnessing the profound benefits of functional mushrooms, ensuring widespread access to our natural, high-quality products.
03
To unlock the powerful medicinal properties of fungi that have been used for millennia using our cutting-edge biotechnology that enables the controlled cultivation of functional mushrooms at scale.
To democratize the benefits of functional mushrooms and other bioproducts together, making them available to anyone, anywhere.
• Compact Size: The bioreactor's small footprint allows it to fit easily on a kitchen countertop, much like a common household appliance.
• Ease of Use: Designed for simplicity, it operates with minimal user input and does not require specialized knowledge or training.
• Reduced Equipment Needs: It eliminates the need for costly sterilization equipment and complex setup, reducing both initial and ongoing costs.
• Faster Production Cycle: Our bioreactor is an accelerator which reduces the cultivation cycle to just 8 days, versus traditional methods which require the growing of mushroom fruiting bodies in a substrate along with extraction which takes from several weeks to months to perform.
• Consistency: Our bioreactor produces pure and measurable quantities of the active alkaloids, allowing consumers accurate and repeatable dosages every time.
This product model is designed to support rapid growth and adaptability, ensuring that Hypha Labs can quickly respond to changes in market demand and regulatory conditions while maintaining a strong customer connection through direct sales and engagement.
“Razor and Blade” Model:
The bioreactor is powered by our proprietary cultivation kits that are delivered sterile and ready to grow. Each kit will include everything needed to grow mycelium from spore to harvest. Subsequent harvests will require the purchase of a new cultivation kit either one at a time or with a subscription.
The bioreactor operates with a user-friendly interface powered by a Raspberry Pi computer and is managed through an app that connects to the cloud. This setup provides consumers with easy-to-follow instructions and a "set and forget" growing process.
Each kit arrives sterile, eliminating the need for HEPA-filtered labs, laminar flow hoods, and extensive sterilization protocols. Consumers can grow mycelium in “pearls" that mature in just eight days, ready for harvest and consumption, providing a fast turnaround not typical in traditional cultivation methods.
The U.S. market for functional mushrooms presents a promising and rapidly expanding opportunity, driven by the increasing consumer interest in these products.
The functional mushroom industry experienced significant growth, reaching a market value of $34.0 billion in the United States in 2023.
The world-wide market for functional mushrooms is forecasted to reach a substantial value of $65.0 billion by the year 2030.
The US market is expected to continue its rapid expansion, with a projected compound annual growth rate (CAGR) of 12.5% between 2023 and 2030.
This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms but the rapid growth and benefits of functional mushrooms.
A. STONE DOUGLASS CEO|CFO
Mr. Douglass is currently the Chairman and CEO of GeoSolar Technologies, Inc. He is also the Chairman and Sealand Natural Resources, Inc., a producer of birch water and other alternative beverages. He was the CEO of over 25 private and public companies, including Spy Optics, RedEnvelope, Vison America, and Piper Aircraft. He graduated with a degree in Business from Fairleigh Dickinson University in 1970.
JOHN FRAILEY CHIEF TECHNICAL
DIRECTOR
John Frailey’s rich professional background spans both large Fortune 100 companies and startups, providing a comprehensive perspective on innovation and scalability in technical endeavors. These achievements underscore John Frailey’s commitment to driving impactful change through technological innovation and position him as an invaluable asset in the pursuit of pioneering smart connected bioreactor solutions in the biotech startup realm.
DENNIS HARTMAN CHIEF LEGAL OFFICER
Dennis Hartmann is a graduate of the University Of Texas School Of Law (Austin Texas) and was a member of the Texas Law Review. His primary focus has been complex business litigation in the areas of real estate, fraud, breach of fiduciary duty, entertainment, employment, intellectual property, partnership dissolution, pursuing fraudulent conveyances and breaking offshore trusts to dismantle vehicles with no purpose other than to hide assets. Mr. Hartmann has been awarded multi-million judgments after a full trial on the merits. Mr. Hartmann is currently overseeing collection of a $264 million judgment awarded in the Florida district court.
CRAIG ELLINS CHIEF SCIENCE OFFICER
Mr. Craig Ellins is renowned for business start-ups in emerging technologies and industries. From pioneering one of the first 24-hour shopping networks to developing one of the internet’s first streaming video technologies, Mr. Ellins has spent more than 30 years creating businesses with a vision toward the future. He most recently served as founder and CEO of One World Pharma, Inc., where he built one of the largest hemp growing facilities based in Columbia, South America. Prior to this venture, he served as CEO and Chief Innovation Officer at GB Sciences, Inc.; and Chairman of Phototron, Inc. Mr. Ellins began his career by building and launching Auto Check Center, an auto smog check center based in Los Angeles, CA before becoming a founder and CEO of HelloNetwork, one of the first video streaming companies to hit the Internet. Mr. Ellins is known for his efforts in pioneering new products for emerging markets.
The information presented in this document is sensitive and confidential. These materials are provided for the exclusive use of those who have received it for the purpose of evaluating Hypha Labs, Inc. (the “Company”). This document may not be reproduced, duplicated or revealed, in whole or in part, or used in any other matter or for any other purpose without the prior written consent of the Company. These materials are being provided for informational purposes only, are intended to be a summary of certain aspects of our business, and do not purport to be all-inclusive or contain all of the information about our business. These materials do not constitute an offer to sell to, or a solicitation of an offer to buy from any person, any securities in any state or other jurisdiction. Any offer or sale will only be made pursuant to a mutually acceptable written securities purchase or other agreement executed by the parties.
In addition, these materials include certain projections and forward-looking statements with respect to the anticipated future performance of the Company. Such projections and forward-looking statements reflect various assumptions concerning the future performance of the Company, and are subject to significant legal, business, economic and competitive uncertainties and contingencies, many of which are beyond the control of the Company. Accordingly, there can be no assurance that such projections and forwardlooking statements will be realized. The actual results may vary from the anticipated results and such variations may be material. No representations or warranties are made by the Company, or any its directors, officers, employees, affiliates or representatives as to the accuracy or reasonableness of such assumptions or the projections or any forward-looking statements based thereon. Only those representations and warranties that are made in a definitive written agreement relating to an investment in the Company, when and if executed, and subject to any limitations and restrictions as may be specified in such definitive agreement, shall have any legal effect.